Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges (2016 - 2025)
Historic Amortization of Deferred Charges for Ligand Pharmaceuticals (LGND) over the last 14 years, with Q3 2025 value amounting to $447000.0.
- Ligand Pharmaceuticals' Amortization of Deferred Charges rose 23358.21% to $447000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $880000.0, marking a year-over-year increase of 12278.48%. This contributed to the annual value of $486000.0 for FY2024, which is 10250.0% up from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Amortization of Deferred Charges of $447000.0 as of Q3 2025, which was up 23358.21% from $125000.0 recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $4.9 million in Q1 2021 and a low of $64000.0 during Q2 2023
- Over the past 5 years, Ligand Pharmaceuticals' median Amortization of Deferred Charges value was $137000.0 (recorded in 2022), while the average stood at $1.0 million.
- Per our database at Business Quant, Ligand Pharmaceuticals' Amortization of Deferred Charges crashed by 9751.89% in 2022 and then skyrocketed by 23358.21% in 2025.
- Over the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $3.8 million in 2021, then crashed by 97.52% to $95000.0 in 2022, then dropped by 14.74% to $81000.0 in 2023, then skyrocketed by 112.35% to $172000.0 in 2024, then surged by 159.88% to $447000.0 in 2025.
- Its Amortization of Deferred Charges was $447000.0 in Q3 2025, compared to $125000.0 in Q2 2025 and $136000.0 in Q1 2025.